Expression of MIRNA-221 in non-small cell lung cancer tissues and correlation with prognosis

Chinese Journal of Lung Cancer

Volumn 17, Issue 3, 2014, Pages 221-225

  Lv, Junjie ^a,b   Xu, Lei ^a   Xu, Youtao ^a   Qiu, Mantang ^a   Yang, Xin ^a   Wang, Jie ^a   Yin, Rong ^a   Xu, Lin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gene expression; Lung neoplasms; miRNA 221; Prognosis

Indexed keywords

MICRORNA 221;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CHI SQUARE TEST; DOWN REGULATION; GENDER; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SMOKING; UNIVARIATE ANALYSIS;

EID: 84940359095     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.l009-3419.2014.03.07     Document Type: Article

References (18)

1. Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer. J Pathol, 2011, 223(2): 102-115.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2): 281-297.
3. Osman A. MicroRNAs in health and disease-basic science and clinical applications. Clin Lab, 2012, 58(5-6): 393-402.
4. Liu J, Zheng M, Tang YL, et al. MicroRNAs, an active and versatile group in cancers. IntJ Oral Sei, 2011, 3(4): 165-175.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006, 6(ll): 857-866.
6. Garofalo M, Quintavalle C, Romano G, et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med, 2012, 12(1): 27-33.
7. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001, 25(4): 402-408.
8. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5): 277-300.
9. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol, 2007, 8(9): 784-796.
10. Vora N, Reckamp KL. Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol, 2008, 35(6): 590-596.
11. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kipl) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J, 2007, 26(15): 3699-3708.
12. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kipl protein levels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
13. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kipl. J Biol Chem, 2008, 283(44): 29897-29903.
14. Fu X, Wang Q, Chen J, et al. Clinical significance of miR-221 and its inverse correlation with p27(Kipl) in hepatocellular carcinoma. Mol Biol Rep, 2011, 38(5): 3029-3035.
15. Chen Y, Zaman MS, Deng G, et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila), 2011, 4(l): 76-86.
16. Hong F, Li Y, Xu Y, et al. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res, 2013, 41(1): 64-71.
17. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 2008, 27(27): 3845-3855.
18. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16(6): 498-509.